General Nephrology
General nephrology news, cross-cutting research, and notable developments across the breadth of kidney medicine, curated by ASNRT.
Browse all news
Explore the full ASNRT newsroom for society announcements, KDIGO guideline updates, AJNT issue releases, and notable developments across the breadth of nephrology.
Latest in this topic
The most recent evidence summaries curated by ASNRT on this topic:
Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. · Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus · Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. · A New Avenue for the Long-Term Upstream Inhibition of the Renin-Angiotensin-Aldosterone System by Inhibiting Angiotensinogen RNA. · Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment. · CAR-T cell therapy in nephrology. · EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. · Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis · Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. · Tirzepatide and Kidney Protection in Obesity: Unanswered Questions. · In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus. · Benefit-harm trade-offs of intensive versus standard blood pressure control: pooled individual-participant analysis · Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline · Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy · Intensive systolic blood pressure reduction and kidney and cardiovascular outcomes (CRHCP secondary analysis) · APOL1 Kidney Disease: Conclusions from a KDIGO Controversies Conference · Validation of BCMA-CD19 Compound CAR-T Therapy in SLE Overlap Syndrome: Over 1.5-Year Follow-Up. · Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes. · Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome. · Women and kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. · CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes. · Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials · Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes · Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study. · Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. · [Nephrology : what's new in 2024 (II)]. · Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials · ISCN 2024 - An International System for Human Cytogenomic Nomenclature (2024). · Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology · Glucagon-like peptide-1 receptor agonists and kidney outcomes. · Hyponatraemia-treatment standard 2024. · Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes across the Spectrum of Kidney Disease: A Systematic Review and Meta-Analysis. · Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1-Mediated Kidney Disease (JUSTICE) · Characterizing Patients Presenting on Hospital Admission With Central Line-Associated Bloodstream Infections: A Multicenter Study. · A Randomized Trial of Intravenous Amino Acids for Kidney Protection · Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial · Systemic Lupus Erythematosus: A Review. · Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. · Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. · Hepatorenal Syndrome in Cirrhosis.